Category Archives: Psyche Ward

How the Establishment is going to take away our Guns

Leave a reply

So far we can approximate, as of today (2019) that 25% of Americans (and growing) won’t be able to get guns because of their mental health record.

Overall, the researchers estimated that 16.7 percent of the 242 million adults in the United States filled at least one psychiatric drug in 2013, including:

  • 12 percent who reported filling one or more prescriptions for antidepressants;
  • 8.3 percent who reported filling one or more prescriptions for sedatives, hypnotics, and anxiolytics; and
  • 1.6 percent who reported filling one or more prescriptions for antipsychotics.

According to the research letter, the rates at which individuals reporting filling prescriptions for psychiatric drugs varied by race and ethnicity. The researchers found that:

  • 20.8 percent of white adults reported using psychiatric drugs;
  • 9.7 percent of black adults reported using psychiatric drugs;
  • 8.7 percent of Hispanic adults reported using psychiatric drugs; and
  • 4.8 percent of Asian adults reported using psychiatric drugs.

Further, the researchers found that the rate of psychiatric drug use increased by age. According to the study, 25.1 percent of adults ages 60 to 85 used at least one psychiatric drug, compared with 9 percent of those ages 18 to 39. The researchers also found that older adults were more likely to use antidepressants and anxiolytics, sedatives, and hypnotics, but not antipsychotics.

In addition, the researchers found that women were more likely than men to report using psychiatric drugs, at 21 and 12 percent, respectively.

According to the research letter, most individuals who reported using psychiatric drugs said they used the medications long-term. The researchers ound that 84.3 percent of adults filled three or more prescriptions for psychiatric drugs in 2013 or reported that they had started to take the drugs in 2011 or earlier. Long-term psychiatric drug users filled a mean of nearly 10 prescriptions for the drugs in 2013.  READ MORE…

(JAMA STUDY 2013 1 out of 6 adults are on psyche drugs)

These data show 1 of 6 US adults reported taking psychiatric drugs at least once during 2013, but with 2- to 3-fold differences by race/ethnicity, age, and sex. Moreover, use may have been underestimated because prescriptions were self-reported, and our estimates of long-term use were limited to a single survey year.

VLA comment:  That is 16.666% of US adults in 2013 that will not be able to get a gun permit.

How much has that increased six years later?  Say 20% of American Adults can’t get gun permits because they have been diagnosed with some form of mental illness and have been prescribed drugs.

Up to 23.5 percent of all children under age 18 take at least one prescription medication each month,1 including opioids, antidepressants, and other psychotropic medications.

We may already be at one quarter (1/4) of the population on psyche drugs.  Be careful with the legislation as this is the subtle alternative way to take away guns.  So far we can approximate that as of today (2019) 25% of Americans won’t be able to get guns because of their mental health record.

THE CAUSE OF MASS SHOOTINGS, SUICIDES CAN BE FOUND IN THE FIELD OF PHARMACOGENETICS (READ POSTS)

 

PHARMACOGENETICS: MASS SHOOTERS HAVE ONE THING IN COMMON

Leave a reply

Nearly all mass shooters have one thing in common, and it isn’t guns
Mike Adams There’s a common thread that winds its way across nearly all mass shooters who carry out violence in America. It’s not guns, it’s psychiatric drugs

Multiple credible scientific studies going back more than a decade, as well as internal documents from certain pharmaceutical companies that suppressed the information show that SSRI drugs ( Selective Serotonin Re-Uptake Inhibitors ) have well known, but unreported side effects, including but not limited to suicide and other violent behavior. One need only Google relevant key words or phrases to see for themselves. www.ssristories.com is one popular site that has documented over 4500 ” Mainstream Media ” reported cases from around the World of aberrant or violent behavior by those taking these powerful drugs.

And what is the science behind this:  PHARMACOGENETICS

CCHR: More About Psychiatric Drugs Causing Violence and Suicide

Leave a reply

  “Antidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family“
  by Yolande Lucire and Christopher Crotty
  Pharmacogenomics and Personalized Medicine, 1 August 2011

This research paper details patients who had been referred to Dr. Lucire’s practice for expert opinion or treatment. More than 120 subjects were diagnosed with akathisia [a neurotoxic psychosis often characterized by a feeling of inner restlessness and inability to stay still] or serotonin toxicity [extremely high levels of serotonin causing toxic and potentially fatal effects] after taking psychiatric drugs that had been prescribed for psychosocial distress. Akathisia has been known to be associated with suicide since the 1950s and with homicide since 1985.

They were tested for variant alleles in cytochrome P450 (CYP450) genes, which play a major role in the metabolism of all antidepressant and many other drugs, indicating ultrarapid metabolism due to allele duplications. This seems to be strongly associated with a large number of deaths from intoxication and suicide. High or fast-changing levels of psychotropic substances can cause unpredictable toxicity leading to violent behavioral effects, including akathisia. [An allele is one of two or more alternative forms of a gene that arise by mutation and are found at the same place on a chromosome.]

 

Read more…

Medical/Legal: Pharmacogenetics-THE AUTOMATON DEFENSE

Leave a reply

With the exception of liability without fault, which requires only actus reus, a crime requires two elements, actus reus and mens rea. While most criminal defenses attempt to excuse, justify or exculpate the defendant’s criminal guilt by addressing mens rea, the automatism defense is different in that it attempts to prove that the defendant did not actually commit actus reus. Automatism can therefor apply to both conventional cases and cases of strict liability & vicarious liability. If the defendant is found to have been acting as an automaton (“a machine that moves”) when the crime was committed, that is, totally unconsciously and involuntarily, then he cannot be said to have been “acting” at all, in a legal sense. And without actus reus, the defendant cannot be held criminally liable for his actions.

READ MORE…

VLA COMMENT:  The rise of information about pharmacogenetics (see room on right side list on this site) citing the inability of individuals to metabolize the popular pharmacueticals leading to mass shootings, suicides will give the legal professional plenty of business for those who have ears to hear!

We are at the cutting edge of its exposure right now in 2019/20.  Attorney’s get educated and open up several bank accounts in different  banks.

Suicides & homicides on pharma drugs

Dr. Lucire’s study:  Having gained access through many attorneys of clients who were convicted of homicide, Dr. Lucire, an Australian Psychiatrist and researcher into pharmacogenetics, shares her study of men and women, finally, taken off their prescription drugs, who relate heinous (emphasis added) homicidal ideations that led them to kill their loved ones.

Excerpt:

Subject 1, in her own words:

My husband was drinking. I took small doses of valerian for a month and had weird dreams and premonitions. When I took nortriptyline, I immediately wanted to kill myself, talked myself out of it. I’d never had thoughts like that before. My husband was angry, shouting. I walked outside a lot, with palpitations, trouble breathing, and became more depressed. My smoking went up to 25 a day, no alcohol. I didn’t sleep for two nights, dreamt, then slept maybe three hours, felt awful. I dreamt that my daughter had dark teeth and I saw a black halo around her head, a spear hanging over it. I felt like a zombie. I believed I had to help my daughter, that a bad spirit possessed her. I picked up a knife and stabbed her and woke up. I was not myself. I was looking on from the outside, controlled by dark forces. She said: “Mum, what are you doing here?” I realized what I’d done. I asked my husband to kill me. He called the police. I felt better in the police cells without the pills, but the pills started again and thoughts of killing myself returned.

 

CCHR NEWSLETTER: Psychiatric Inpatients Have Elevated Risks for Adverse Reactions

Leave a reply

Psychiatric Inpatients Have Elevated Risks for Adverse Reactions

 

Posted on by cchrstl

[Reference: “Multiple adverse outcomes following first discharge from inpatient psychiatric care: a national cohort study”, The Lancet Psychiatry, June 03, 2019]

“People discharged from inpatient psychiatric care are at higher risk than the rest of the population for a range of serious fatal and non-fatal adverse outcomes.”

These individuals are also more likely to perpetrate violent crimes, including homicide. Suicide risk is known to be especially raised soon after discharge.

READ NEWSLETTER

VLA commewnt:

I would encourage eveRyone to go to our pharmacogenetic “room”.  Millions of inpatients are being given  modern drugs for diagnoses of Bipolar, ADHD that they can’t metabolize.  By giving the inpatients drugs that are cookie cutter prescribed without the duty to care genetic test to see if the drug they are being prescribed can be adequately metabolized.  Cultural groups such as Caucasian, African Americans, Asians have different panels of enyzmes per culture.  For example 10% of Caucasians are genetically missing the liver enzyme that metabolized common psychiatric drugs such as Haldol, Respiradol, Adderall and street drugs such as cocaine, psyilosybn, LSD, etc.  When given cookie cutter prescriptions, taken on a daily  basis,  this demographic begin to have suicidal or homicidal ideations because the drug is accumulating in the body, not able to transduce by enzymatic activity into a harmless substance to be excreted out by the kidneys.

 

FDA Approves electroshock device for kids 7-12 who have been diagnosed as ADHD

Leave a reply

The U.S. Food and Drug Administration (FDA) approved on April 19, 2019 a medical device for so-called attention deficit hyperactivity disorder (ADHD). The prescription-only device, called the Monarch external Trigeminal Nerve Stimulation (eTNS) System from NeuroSigma, is for patients ages 7 to 12 years old who are not currently taking prescription ADHD drugs.

This device delivers an electric current to the brain (through the V1 branch of the 5th cranial nerve) with an electrode taped to the forehead. It costs about $900 to start, with additional costs for more of the electrode patches which are only used once each. It is not currently reimbursed by insurance.    READ MORE…

VLA Comment: Well here we are Humanity…little lab rats!  Poison them kids, dogs and
plants too (vaccines, gmo food, geoengineering, fluoride, pesticides,
herbicides) them-disable them-electrocute them…and the new infanticide
 bills…kill them immediately)*

Cytochrome P450: Physiological and pharmacological role in Mental Illness, Cancer, Parkinson

Leave a reply

Suicides and homicides data

Images of School shooters

The cytochrome P450 isoenzymes are a superfamily of enzymes found in the Liver and in all cells except the blood.  These enzymes catalyse the metabolism of a large number of endogenous and exogenous compounds-prescription drugs and street drugs.

The vast individual variation of genetics vary greatly according to race and ethnicity.  It is the field of PHARMACOGENETICS that accounts for surge in “apparent” mental illness, suicides, drug addiction and homicides and disease susceptibility.

About 5–10% of Caucasians and 0.9% ofAsians metabolise debrisoquine and other substrates of CYP2D6 at a markedly decreased rate. In addition to thepoor and extensive metabolisers, a group called the ultrarapid metabolisers has been identified.

The CYP2C19 enzyme is also associated with genetic polymorphism. Slow metabolisers  are found in 2–5% of Caucasians, about20% of the Japanese population, 19% of African Americansand 8% of Africans [18].

Cytochrome P450: Physiological and pharmacological role READ THIS Study:

READ ALL OUR POSTS ON PHARMACOGENETICS

 

Killer Drugs? Homicide Risk Linked to Medications

Pharmacogenetics (gene testing): Attorney’s are now stepping up!

Leave a reply

Medical DNA sequencing leads to lawsuits and legal questions

One of the biggest concerns is legal liability. Health care providers face a disconnect: Technology has outpaced their ability to interpret genetic results, such as a patient’s risk of breast cancer or heart attack from a particular mutation. Because of that, typical fallbacks including providing a rigorous standard of care—which can also act as a legal shield against malpractice claims—are becoming fuzzy. What is a doctor to do when a patient has results from a direct-to-consumer testing company like 23andMe and asks what implications they have for their health? Or when a lab notifies a doctor that a genetic variant their patient carries, thought meaningless 3 years ago, is now known to be harmful, but they can’t locate the patient? Can a testing lab be held liable for not regularly reviewing the scientific literature, to track science’s understanding of the gene variants it tests for?

Read more…

 

LawSeqSM: Building a Sound Legal Foundation for Translating Genomics into Clinical Application

This innovative 3-year project, based cooperatively at the University of Minnesota and Vanderbilt University, has convened a national Working Group of top legal and scientific experts to analyze current US federal and state law and regulation on translational genomics and to generate consensus guidance on what the law should be.

 

PHARMACOGENETIC TEST SIGNIFICANTLY INCREASE REMISSION OF MENTAL ILLNESS (DEPRESSION)

1 Reply

GeneSight employs a proprietary algorithm to analyze 12 genes and assess how they impact patients’ ability to process dozens of psychotropic medications. The test report buckets depression treatments as red (significant gene-drug interaction), yellow (moderate gene-drug interaction), or green (use as directed.) When the test report shows that patients are on red or yellow medications, their doctors should consider changing the drug or dose, while patients on green medications don’t require a medication change.

Researchers further evaluated patients who entered the study on red medications and either remained on red medications or were switched to yellow or green drugs. Remission rates were 153 percent higher, response rates were 71 percent higher, and symptom improvement rates were 59 percent higher when patients were switched from red to yellow or green meds — all statistically significant changes.

This analysis “establishes a new standard of care” for physicians by demonstrating that patients on red medications must be identified and have their medications modified, said Dechairo. “This switching analysis has also been an important point in our payor discussions, as utilization management programs can focus on switching patients from red medications, which would deliver results even better than those in the GUIDED study,” he said.

One prior cost-effectiveness study using drug claims data showed that using GeneSight can increase treatment adherence and save an average of $1,036 per year per patient, while another study using commercial claims data showed GeneSight’s potential to save $1,556 per patient by reducing disability claims, medical utilization, workplace absence.

Currently, the more than 300,000 GeneSight tests Myriad sells per year are largely ordered by psychiatrists. Once there is greater reimbursement traction, Myriad is planning a significant marketing push into the primary care market, including direct-to-patient advertising for the test, according to Capone.

GeneSight, which is a lab-developed test (LDT) performed in a CLIA-certified lab, must be ordered by physicians.

Capone noted that the FDA has publicly stated that it will continue to practice enforcement discretion for LDTs, and leave it up to legislators to reform diagnostic regulations that may or may not bring LDTs under the agency’s oversight. In December, legislators in the House of Representatives and the Senate incorporated the FDA’s ideas for diagnostics regulatory reform into a draft bill that features a pre-certification program that labs could use to bring the majority of new diagnostics to market, while having to submit around 10 percent of tests for premarket review.  READ MORE…

ABSTRACT OF STUDY